Non-invasive ocular RNAi delivery

Article

RXi and EyeGate have announced a collaboration focused on non-invasive ocular delivery of RNAi therapeutics. Both companies will contribute technology, expertise and resources to the partnership.

RXi and EyeGate have announced a collaboration focused on non-invasive ocular delivery of RNAi therapeutics. Both companies will contribute technology, expertise and resources to the partnership.

The companies will explore the use of EyeGate's iontophoresis technology to deliver RXi's sd-rxRNA compounds to the eye in preclinical models. Iontophoresis technology is a method of drug delivery that uses a low-level electrical current to deliver a drug across the ocular surface into the eye. Once in the eye it is believed that the sd-rxRNA compounds will enter the retinal cells and silence disease causing genes.

President and CEO of RXi, Noah D. Beerman, explained: "In pre-clinical studies, our sd-rxRNA (or self-delivering rxRNA) compounds have shown effective gene silencing in the retina following intraocular injection. Combining our RNAi technology with EyeGate's unique, non-invasive ocular delivery system (EyeGate II), provides us with the potential opportunity to develop novel treatments for many ocular diseases and to improve treatment options."

Stephen From, president and CEO of EyeGate Pharma, added: "Our collaboration with RXi will enable us to expand the drug delivery options for the EyeGate II delivery system into RNAi therapeutics, developing new uses and markets for the device…"

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.